Old Web
English
Sign In
Acemap
>
authorDetail
>
Prasanna Kumar Nidamarthy
Prasanna Kumar Nidamarthy
Novartis
Internal medicine
Medicine
Clinical endpoint
Nilotinib
Immunology
6
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
2021
The Lancet Haematology
Antonio M. Risitano
Alexander Röth
Juliette Soret
Camilla Frieri
Flore Sicre de Fontbrune
Luana Marano
Ferras Alashkar
Lina Benajiba
Serena Marotta
Izabela Rozenberg
Julie Milojevic
Peter End
Prasanna Kumar Nidamarthy
Guido Junge
Régis Peffault de Latour
Show All
Source
Cite
Save
Citations (5)
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors.
2021
Clinical Therapeutics
Victor Moreno
Richard Greil
Jeffrey Yachnin
Margarita Majem
Martin Wermke
Hendrik-Tobias Arkenau
Jean-Rene Basque
Prasanna Kumar Nidamarthy
Shruti Kapoor
Xiaoming Cui
M. Giovannini
Show All
Source
Cite
Save
Citations (1)
Efficacy and Safety of Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTxtnd Interim Analysis
2014
Blood
Timothy P. Hughes
Eduardo Munhoz
Alaa Elhaddad
Ong Tee Chuan
Kudrat Abdulkadyrov
Jake Shortt
Hang Quach
Carolina Pavlovsky
Vernon J. Louw
Luis Meillon
Lee-Yung Shih
Turkina Ag
Jonathan Hwang
Prasanna Kumar Nidamarthy
Darshan Dalal
Jeffrey H. Lipton
Show All
Source
Cite
Save
Citations (0)
1